

References

Brian T. Luke (lukeb@ncifcrf.gov)

[Ada-02] Adam B, Qu Y, Davis JW, Ward MD, Clements MA, *et al.* Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. *Cancer Research* 2002;62:3609-14.

[Bag-05] Baggerly KA, Coombes KR, Morris JS. Bias, randomization, and ovarian proteomic data: a reply to “producers and consumers.” *Cancer Informatics* 2005;1:9-14.

[Ban-05] Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, Thompson D, *et al.* Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. *Clin Chem* 2005;51:1637-49.

[Bas-83] Bast RC, Klug TL, St.John E, Jenison E, Niloff JM, Lazarus H, *et al.* A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. *N Engl J Med* 1983;309:883-7.

[Boe-07] Boersma B, Reimers M, Yi M, Ludwig J, Luke B, Stephens R, Yfantis H, Lee D, Weinstein J, Ambs S. A Stromal Gene Signature Associated with Inflammatory Breast Cancer and Disease Outcome. *Int J Cancer* 2007; submitted for publication.

[Bon-05] Bons JAP, de Boer D, van Dieje-Visser MP, Wodzig WKWH Standardization of calibration and quality control using surface enhanced laser desorption ionization-time of flight-mass spectrometry. *Clin Chim Acta* 2005;366:249-56.

[Bro-05] Brouwers FM, Petricoin EF 3rd, Ksinantova L, Breza J, Rajapakse V, Ross S, *et al.* Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. *Endocr Relat Cancer* 2005;12:263-72.

[Cal-05] Calvo KR, Liotta LA, Petricoin EF. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. *Biosci Rep* 2005;25:107-25.

[Cat-94] Catalona WJ, Smith, DS. Five year tumour recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. *J Urol* 1994;152:1837-42.

[Caz-02] Cazares LH, Adam BL, Ward MD, Nasim S, Schellhammer, PF, Semmes OJ, *et al.* Normal, Benign, Preneoplastic, and Malignant Prostate Cells Have Distinct Protein Expression Profiles Resolved by Surface Enhanced Laser Desorption/Ionization Mass Spectrometry. *Clin Cancer Res* 2002;8:2541-52.

[Cha-04] Chan KC, Lucas DA, Hise D, Schaefer CF, Xiao Z, Janini GM, *et al.* Analysis of the Human Serum Proteome. *Clin Prot J.* 2004;1:101-225.

[Con-04] Conrads TP, Fusaro VA, Ross S, Johann D, Rajapakse V, Hitt BA, et al. High-resolution serum proteomic features for ovarian cancer detection. *Endocr Relat Cancer* 2004;11:163-78.

[Esp-05] Espina V, Geho D, Mehta AI, Petricoin EF 3rd, Liotta LA, Rosenblatt KP. Pathology of the future: molecular profiling for targeted therapy. *Cancer Invest* 2005;23:36-46.

[Gul-06] Gulmann C, Sheehan KM, Kay EW, Liotta LA, Petricoin, E. F., 3rd. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. *J Pathol* 2006;208:595-606.

[Hab-06] Habermann JK, Roblick UJ, Luke BT, Prieto DA, Finlay WJ, *et al.* Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. *Gastroenterology*, 2006;131:1020-9.

[Han-03] Hanash S. Harnessing immunity for cancer marker discovery. *Nature Biotechnol* 2003;21:37-8.

[Ho-06] Ho DW, Yang ZF, Wong BY, Kwong DL, Sham JS, Wei WI, et al. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry serum protein profiling to identify nasopharyngeal carcinoma. *Cancer* 2006;107:99-107.

[Hon-05] Hong H, Dragan Y, Epstein J, Teitel C, Chen B, Xie Q, et al. Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of-flight (TOF) mass spectrometry (MS). *BMC Bioinformatics* 2005;6(Suppl 2):S5.

[Hor-05] Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice. *Clin Chem* 2005;51:3-5.

[Koh-88] Kohonen T. *Self-Organizing and Associative Memory*. 2nd ed. New York (NY): Springer-Verlag; 1988.

[Kru-52] Kruskal WH and Wallis WA. Use of ranks in one-criterion variance analysis. *J. Am. Stat. Assoc.* 47(260):1952;583-621.

[Liu-05] Liu W, Guan M, Wu D, Zhang Y, Wu Z, Xu M, Lu Y. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. *Eur Urol* 2005;47:456-62.

[Luk-07] Luke BT, Collins JR, Habermann JK, Prieto DA, Veenstra TD, Ried T. Comparing biomarkers and proteomic fingerprints for classification studies. *J Natl Cancer Inst* 2007; submitted.

[Mak-04] Mak T, Laloo F, Evans DG, Hill J. Molecular stool screening for colorectal cancer. *Br J Surg* 2004;91:790-800.

[Mit-05] Mitchell BL, Yasui Y, Li CI, Fitzpatrick AL, Lampe PD. Impact of freeze-thaw and storage times on plasma samples used in mass spectrometry based biomarker discovery projects. *Cancer Inform* 2005;1:98-104.

[Orn-04] Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. *J Urol* 2004;172:1302-5.

[Pet-03] Petricoin EF, Fishman DA, Conrads TP, Veenstra TD, Liotta LA. Proteomic pattern diagnostics: Producers and consumers in the era of correlative science. *BMC Bioinformatics* 2003;4:24/comments.

[Pet-04] Petricoin EF, Rajapaske V, Herman EH, Arekani AM, Ross S, Johann D, et al. Toxicoproteomics: serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection. *Toxicol Pathol* 2004;32(Suppl 1); 122-30.

[Pet-05] Petricoin EF 3rd, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, et al. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. *J Clin Oncol* 2005;23:3614-21.

[Pou-97] Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control. *Urol Clin North Am* 1997;24:395-406.

[Rai-05] Rai AJ, Stemmer PM, Zhang Z, Adam BL, Morgan WT, Caffrey RE, et al. Analysis of human proteome organization plasma proteome project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: Multi-institution correlation of spectra and identification of biomarkers. *Proteomics* 2005;5:3467-74.

[Ran-04] Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. *Nature Rev Cancer* 2004;4:309-14.

[Ran-05a] Ransohoff DF. Lessons from controversy: ovarian cancer screening and serum proteomics. *J Natl Cancer Inst* 2005;97:315-9.

[Ran-05b] Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. *Nature Reviews: Cancer* 2005;5:142-9.

[Sch-02] Schulmann K, Reiser M, Schmiegel W. Colonic cancer and polyps. *Best Pract Res Clin Gastroenterol* 2002;16:91-114.

[Sem-05] Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. *Clin Chem* 2005;51:102-112.

[Sri-06] Srinivasan R, Daniels J, Fusaro V, Lundqvist A, Killian JK, Geho D, et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. *Exp Hematol* 2006;34:796-801.

[Sto-05] Stone JH, Rajapakse VN, Hoffman GS, Specks U, Merkel PA, Spiera RF, et al. *Arthritis Rheum* 2005;52:902-10.

[Sun-06] Sundsten T, Eberhardson M, Goransson M, Bergsten P. The use of proteomics in identifying expressed serum proteins in humans with type 2 diabetes. *Proteome Science* 2006;4:22.

[Tra-94] Trapasso JG, Dekernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. *J Urol* 1994;153:1821-1825.

[War-06] Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, *et al.* Identification of serum biomarkers for colon cancer by proteomic analysis. *Br J Cancer* 2006;94:1898-905.

[Wul-06] Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF 3rd. Technology Insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays. *Nat Clin Pract Oncol* 2006;3:256-68.

[Yan-05] Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. *BMC Cancer* 2005;5:83.

[Yip-03] Yip KY, Cheung DW, Ng MK. A highly-usable projected clustering algorithm for gene expression profiles. 3rd ACM SIGKDD Workshop on Data Mining in Bioinformatics 2003;41-8.

[Yu-05] Yu Y, Chen S, Wang LS, Chen WL, Guo WJ, Yan H, et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. *Oncology* 2005;68:79-86.